H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) with a $35 price target.

​The analyst noted the promising potential of the company’s Zorevunersen for treating Dravet syndrome as one of the key reasons behind their bullish sentiment. Ghosh highlighted that the drug’s 36-month open-label extension data showed long-term reduction in major motor seizure frequency along with cognitive and behavioral improvements. The analyst believes these results suggest that the treatment has the potential to become the first disease-modifying therapy for Dravet syndrome.

​In addition, Zorevunersen differentiates itself from the existing treatments due to its primary focus on symptomatic relief.

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotech company that develops RNA-based medicines for treating various diseases by increasing protein expression. Zorevunersen is one of the company’s lead drugs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.